Introduction
Chronic non-cancer pain (CNCP) is common and burdensome. Low back pain, neck pain, and migraines were the first, fourth, and eighth largest contributors, respectively, to global nonfatal health burden (years lived with disability) [1] . CNCP has a major impact on the individual in terms of quality of life, mental health, health status, relationships, and employment [2] [3] [4] .
Short-duration randomized controlled trials have evaluated pharmaceutical opioids in the treatment of a range of CNCP conditions and have demonstrated modest attenuation of pain [5] , but few studies have run for long enough to demonstrate long-term benefit of opioids for CNCP [6] [7] [8] [9] such that there are reasons to question their clinical effectiveness. Despite the limitations of the evidence, there has been a considerable increase in the long-term prescribing of opioids for CNCP in a number of countries [10] [11] [12] [13] [14] . There has also been professional and public concern about concomitant increases in problematic opioid use and harms including dependence [11, [15] [16] [17] .
There are limited data on the patterns of opioid prescribing for individual patients over the longer term [18] . Because they often exclude more complex patients and rarely follow up patients for long enough to capture behaviors that may be indicative of abuse or dependence [19] , clinical trials typically find far lower rates of aberrant drug-related behaviors and opioid dependence than have been reported in some observational studies [20] .
The Pain and Opioid IN Treatment (POINT) cohort is designed to document patterns of pharmaceutical opioid prescribing and risk of adverse events in patients prescribed opioids for CNCP [21] . In this article, the aims were to:
1. Describe levels of current pharmaceutical opioid consumption, and the correlates of different levels of consumption; 2. Examine the prevalence of lifetime dependence and past year dependence as per ICD-10 criteria; and 3. Examine the correlates of the criteria met for pharmaceutical opioid dependence.
Methods

Study Design and Setting
The POINT study is a prospective cohort study of people across Australia who have been prescribed opioids for CNCP; the methodology [21] and characteristics [22] of this cohort have been described in detail elsewhere.
The study was approved by the Human Research Ethics Committee of the University of New South Wales (HREC reference: # HC12149). The study also received A1 Australian National Pharmacy Guild Approval to approach pharmacists to assist with recruitment of participants (Approval n. 815).
Eligibility Criteria
Participants were eligible if they were: 18 years of age or older; fluent in English; mentally and physically able to complete telephone and self-complete interviews; without obvious cognitive impairment; living with CNCP; prescribed an opioid such as morphine, oxycodone, or fentanyl (Schedule 8 in the Australian classification of drugs of dependence; namely drugs that are subject to additional regulatory controls regarding manufacture, supply, distribution, possession, and use [23] ); and having taken such opioids for CNCP for more than 6 weeks.
A history of injecting drug use was not an exclusion criterion, but those currently prescribed methadone or buprenorphine as opioid substitution therapy for heroin dependence were not eligible. Those patients taking opioids for cancer pain were also excluded.
Phone interviews were conducted by assistants who had a minimum 3-year health or psychology degree. Interviewers had received training in the survey instrument and were provided glossaries of chronic pain medications and conditions.
Measures
The measures, tools, and domains collected were based on recommendations of the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) [24, 25] . Full details of the measures used in the study have been reported elsewhere [21] ; however, brief summaries of measures used in the current analyses are provided below.
Pain and Pain-Related Measures
Participants were asked about lifetime and current history of pain conditions. Current pain severity and pain interference were measured by the Brief Pain Inventory [26] , as a continuous score out of 10. Relief from pain provided by current medications was measured as a continuous score from 0% to 100%. The Pain Self-Efficacy Questionnaire [27, 28] provided a score from 0 to 60, with higher scores indicating more confidence in managing life despite pain.
Mental Health and Substance Use
Participants were asked if they had suffered from depression, anxiety or panic attacks or from post-traumatic stress disorder (PTSD) in the past year. Current depression and generalized anxiety disorder were measured by the PHQ-9 and GAD-7 modules of the Patient Health Questionnaire [29] . Validated cutoffs were used as follows: moderate to severe depression was defined as a score of 10 on the PHQ-9 [30] ; moderate to severe anxiety was defined as a score of 10 on the GAD-7 [31] . Participants were screened for potential ICD-10 diagnoses of Borderline Personality Disorder using the National Survey of Mental Health and Wellbeing version of the Composite International Diagnostic Interview (CIDI) [32] . A score of 3 on the Primary Care PTSD screen was used to indicate presence of PTSD [33] .
Participants were asked about lifetime and past year use of alcohol and illicit drugs. Lifetime illicit drug, pharmaceutical opioid, and alcohol use disorders (using ICD-10 dependence criteria, including tolerance and withdrawal) were assessed via the CIDI [34] ) alcohol and illicit drug use module. A binary variable for overdose was created from the question "how many times in your life have you overdosed on any drug?"
The Prescribed Opioids Difficulty Scale (PODS, Appendix A) was used to measure participants' current problems and concerns about using prescribed opioids [35] . A cutoff of 8 was considered a moderate score in which par-ticipants would have endorsed at least two difficulties out of the 15 items [35] . Scores on the Opioid-Related Behaviors in Treatment scale (ORBIT, Appendix B), a 10item measure of aberrant behaviors such as doctor shopping, diversion, and other examples of unsanctioned use of medications, were converted into a dichotomous variable based on endorsement of at least one item [36] .
Medications
Daily oral morphine equivalent (OME) doses for the opioids taken by the cohort were estimated following review and synthesis of a range of clinical guidelines [37] . All Schedule 8, Schedule 4, and over-the-counter medications were included in the calculation. This was based on opioid use recorded in a 1-week medication diary, which was completed as part of the self-complete questionnaire mailed to participants.
Four groups were formed with the following cutoffs: 1-20 mg/day OME, 21-90 mg, 91-199 mg, and more than 200 mg, based on the previous research and guidelines [38, 39] .
Data Analysis
All analyses were planned a priori independent of the data. The analyses were conducted using STATA, version 12.0 (Stata Corporation, College Station, TX, USA). Means, standard deviations and t-tests were used where data were normal; medians, interquartile ranges, Hedges g for effect sizes with 95% Confidence Intervals were used to compare groups where the data were not normally distributed. OME groups were compared using multinomial logistic regression; relative risk ratios, and 95% confidence intervals were used for proportions. The category of 21-90 mg/day OME was used as the reference group in the multinomial regressions, as this range represented usual therapeutic doses and the largest group in the sample.
Two groups were defined according to whether or not they met ICD-10 criteria for pharmaceutical opioid dependence in the past year. Univariate logistic regression models were conducted to compare these groups. Relative risk and Hedges g are reported with 95% CI; a multivariate model was also conducted to determine the independence of associations, adjusted RR and 95% CI are reported. OME was not entered into the regression as we did not have an OME for the whole sample. Further, as all participants that scored moderate-high in the PODS had past 12 month dependence, this could not be included in the analysis).
Results
Participants were recruited through community pharmacies. From a database of 5,745 community pharmacies, researches contacted 5,332 pharmacies across Australia (93%), and 1,868 pharmacies were willing to refer Pharmaceutical Opioid Use and Dependence within the POINT Cohort potentially eligible participants to the study (see [21] for further detail). In total, 33% of pharmacies across Australia agreed to participate ( Figure 1 ). Of those that agreed to participate, 36% of pharmacists sent through details of eligible participants to the POINT team. A random sample of pharmacists (n 5 71) was asked to collect data on the number and characteristics of all customers purchasing opioids during their 6-week recruitment window. We found that of the total number of customers recorded as purchasing opioids in these pharmacies, 52% were female (the POINT cohort was 55% female); and 7% were 18-34 years, 55% 35-64 years, and 38% 651 years (vs 5%, 62%, and 33%, respectively, in the POINT cohort). Of these customers, 63% were prescribed oxycodone (vs 62% in the POINT cohort), 16.5% prescribed morphine (vs 15% in the POINT cohort) fentanyl patches 21% (vs 15% in the POINT cohort), and 24% buprenorphine patches (vs 21% in the POINT cohort). These findings suggest a similarity between the POINT sample and people prescribed opioids for CNCP more generally.
The analysis of opioid consumption presented in this article is based on data from n 5 1,085 participants who returned medication diaries, from which OME mg daily doses could be determined. Analyses of pharmaceutical opioid dependence were based on interviews with n 5 1,424 participants who completed the CIDI to determine ICD-10 dependence.
Of the 1,424 participants who completed the CIDI, there were 299 participants who did not return their medication diary, so OMEs could not be calculated. Participants who did not return their diaries were more likely to be younger ( people who did not return their diary, and therefore not included in analyses of OME, had more complex comorbidities and this must be considered in the following results.
Correlates of Different Levels of Pharmaceutical Opioid Consumption
Participants were divided into four groups based on their daily OME dose: "less than 20 mg" group (n 5 95, 8.8% of the sample), "21-90 mg" group (n 5 565, 52.1% of the sample), "91-199 mg" group (n 5 264, 24.3% of the sample), and "more than 200 mg" group (n 5 161, 14.8% of the sample, Table 1 ). Participants the "91-199 mg" and "more than 200 mg" group were younger than the 21-90 mg group, whereas, those in the "less than 20 mg" group were more likely to be older than those in the "21-90 mg" group.
Both the "91-199 mg" and the "over 200 mg" groups reported higher pain scores, higher pain interference, and lower pain self-efficacy scores than those in the "21-90 mg" group, and the "less than 20 mg" group reported lower pain interference and had higher pain self-efficacy scores (see Figure 1 ). The "91-199 mg" and "over 200 mg" groups reported less relief from their medications than the "21-90 mg" group. The "more than 200 mg" group were less likely to report past year arthritis compared with the "21-90 mg" group, while the "91-199 mg" group were more likely to report chronic back or neck problems than the "21-90 mg" group.
Those in the "over 200 mg" group had 2.7 times the relative risk of being prescribed morphine compared with the "21-90 mg" group; buprenorphine was less likely to be prescribed in the "91-199 mg" and "more than 200 mg" groups compared with the "21-90 mg" group ( Table 1) . The "91-199" and "more than 200 mg" groups were more likely to report a higher median number of prescribed current opioids, while the "less than 20 mg" group reported a lower median number of prescription opioids than the "21-99 mg" group. Side effects were more likely to be reported in the "91-199 mg" and "more than 200 mg" groups, while the "less than 20 mg" group were less likely to report side effects than the "21-90 mg" group (Table 1) .
Participants in the "more than 200 mg" group were more likely to screen positive for current moderate-tosevere depression than participants in the "21-90 mg" group (Table 1) . Participants in the "91-199 mg" and "more than 200 mg" groups were more likely to score intermediate-high on the PODS, indicating more problems with their prescription opioid use, compared with the "21-90 mg" group, while the "less than 20 mg" group scored lower on the PODS. The "91-199 mg" group were more likely to engage in aberrant behaviors, as measured by the ORBIT scale, while the "less than 20 mg" group were less likely to engage in aberrant behaviors than the "21-90 mg" group. The "more than 200 mg" were more likely to meet lifetime and past year criteria for ICD-10 pharmaceutical opioid dependence than the "21-90 mg" group. No one in the "0-20 mg" group met ICD-10 criteria for lifetime or past year pharmaceutical opioid dependence (Table 1) . Ad hoc analyses comparing the '91-199mg' group and the 'more than 200mg' groups found no differences between the two in terms of pain severity, pain interference, time in pain, problems with opioids, aberrance, and dependence. Figure 1 presents associations and locally weighted scatterplot smoothing (LOESS) between OME and pain severity, pain medication relief, time on medication for pain, and pain and self-efficacy scores.
Correlates of ICD-10 Pharmaceutical Opioid Dependence with Past Year Symptoms
Among those who completed the CIDI (n 5 1,424), 8.5% (95% CI 7.2-10.1) met criteria for lifetime ICD-10 pharmaceutical opioid dependence and 4.8% (95% CI 3.8-6.0) met criteria for lifetime ICD-10 pharmaceutical opioid dependence with past year symptoms ( Table 1 ). The median age of onset for ICD-10 opioid use disorder was 40 years [IQR, [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] .
People who met criteria for lifetime ICD-10 opioid dependence with past year symptoms were more likely to be younger, male, unemployed, and less likely to be married or defacto ( Table 2 ). Those who met criteria for ICD-10 opioid use dependence with past year symptoms were currently prescribed a higher median opioid consumption than those who did not. All participants who met criteria for ICD-10 dependence also scored intermediate-to-high for problematic use associated with opioids. They were also more likely to engage in aberrant behaviors, compared with those who did not meet criteria for past year ICD-10 pharmaceutical opioid dependence. The most common aberrant behaviors among participants who met criteria for dependence were asking for an early script renewal (48.5%, n 5 33), and asking doctor for an increase in dose (39.7%, n 5 27, Table 2 ).
Participants who met criteria for past year dependence were more likely also to meet criteria for ICD-10 dependence on alcohol, benzodiazepines, and other illicit drugs (Table 2 ). They were also more likely to report past year depression, GAD, and PTSD. There was a strong association between OME and past year pharmaceutical opioid dependence (120 mg vs 70 mg, respectively, Hedges g 0.54, 95% CI 20.86 to 20.22, Table 2 ). Significant predictors in bivariate analyses were entered into a multivariate logistic regression to examine the factors associated with ICD-10 lifetime pharmaceutical opioid dependence with past year symptoms ( Table 2 ). In the multivariate analyses, those who met criteria for past year pharmaceutical opioid dependence past year were younger; more likely to engage in aberrant behaviours; and were more likely to meet criteria for ICD-10 lifetime benzodiazepine dependence. Note that the multivariate analysis did not include OME due to the Pharmaceutical Opioid Use and Dependence within the POINT Cohort Table 1 Demographics and clinical characteristics of the POINT cohort (n 5 1,085) by mean daily opioid consumption (measured in oral morphine equivalent (OME) mg) number that did not return the medication diary, and the complexity of the participant characteristics that did not return the diaries. We ran a post hoc multivariate analysis including OME which resulted in age (RR 0.96, 95% CI 0.93-0.99) and aberrant behaviors (RR 2.49, 95% CI 1. 18-5.24 ) and ICD-10 lifetime benzodiazepine dependence (RR 4.31, 95%CI 1.55-12.63) remaining significant.
Discussion
Research is needed to address concerns about potential adverse events of chronic opioid therapy, including overdose, dependence, aberrance, and diversion [40] . The POINT study is unique with respect to the detailed data collected on actual consumption of all pharmaceutical opioids, including those obtained without prescription, i.e., over-the-counter opioids sold in pharmacies. This detailed assessment revealed some concerning patterns of opioid consumption, and clear associations between high-level consumption and a range of indicators of poorer functioning. Approximately 15% of the cohort was taking daily doses of more than 200 mg OME and around 40% of the sample was consuming 90 mg OME or more daily. Those taking higher doses had the highest rates of problems with opioid medication, aberrance, and dependence. Concerningly, participants receiving higher OME doses reported less pain relief from their medications than participants on lower consumptions. Not only were there no differences in pain relief, pain severity, time in pain between those consuming 91-199 mg OME per day and those taking more than 200 mg OME, but also there were no differences in rates of aberrance and dependence between these two groups.
Higher current opioid consumption was associated with a range of demographic and substance use characteristics. Correlates of higher opioid consumption were also consistent with factors identified in the literature as being associated with increased overdose mortality risk, including young age, male gender, lower socioeconomic status, and psychiatric comorbidity [41] [42] [43] [44] . They were also consistent with characteristics identified in risk screening tools for opioid prescribing [45] . The term "adverse selection" has been coined to describe this apparent contradiction in which the likelihood of a patient receiving opioid therapy increases as the number of risk factors for adverse outcomes increases [44] ; this study found strong evidence for this, whereby those consuming higher levels of opioids were clearly those with a more complex picture of physical and mental health problems, as well as social disadvantage. Further, in this sample many of the chronic pain patients prescribed higher doses of long-term opioids were concurrently taking other medications (e.g., benzodiazepines) in doses that are considered highrisk for adverse outcomes, and the levels of concomi-tant medications were higher in those taking higher amounts of opioids.
The association of higher opioid consumption with increasing levels of aberrant behaviors (e.g., tampering and nonmedical use) suggests that monitoring by prescribers is warranted [46] . Conversely, the finding that some behaviors such as doctor shopping were rarely reported suggest that, at least in this sample, strategies such as prescription drug monitoring would have limited ability to identify patients at risk.
A minority (8.5% of the sample) met criteria for ICD-10 lifetime pharmaceutical opioid dependence, and 4.7% had features of dependence within the past year. This is consistent with research suggesting that pharmaceutical opioid use disorders affect a minority of CNCP patients prescribed opioids [40] . In this study, past year dependence was associated with many indicators of adverse psychosocial, mental, and physical functioning; it remained independently associated with being younger and having lifetime benzodiazepine dependence, which has important clinical implications for the safety of opioid prescribing.
Universal precautions in opioid prescribing have been widely endorsed internationally and in Australian national guidelines [47, 48] , and provide a uniform approach to risk management based on the fact that chronic pain and substance use disorders often co-occur. Guidelines based on universal precautions often suggest consultation with a pain specialist in cases where high doses (usually more than 120 mg OME per day) appear to be required and in whom improvement in pain and function are not seen. Uptake of these guidelines in practice is generally low, possibly due to challenges in prescriber confidence in managing identified risks. However, this study has clearly demonstrated that there is a significant proportion of CNCP patients taking very high doses of opioids who have multiple risk factors for potential adverse outcomes. Similarly, those meeting criteria for dependence had higher levels of most indicators of poorer well-being. There is clearly a need for increased vigilance and reassessment of the progress and functioning of CNCP patients in whom opioid consumption is considerable and problems related to opioid consumption prominent.
Limitations
This study has a number of strengths, which include the large national sample, with data detailed collected on actual consumption of opioids and OTC medication, thus addressing the common limitation of relying on administrative data for medication use. In addition, carefully selected and validated measures were selected based on the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) [24, 25] .
Nonetheless, there are limitations. The self-report design raises potential issues of both recall and social desirability bias. However, self-report is reliable in the Pharmaceutical Opioid Use and Dependence within the POINT Cohort absence of negative consequences for participants, and is commonly used in research involving sensitive issues where care is needed to minimise concern over confidentiality and judgment [49] . All participants were informed that their responses would be deidentified and confidential, which enhances the validity of selfreported substance use.
Further, OME was not entered into the multivariate analysis to consider current consumption as an independent correlate of pharmaceutical opioid dependence. OME data were only available for 29 out of the 69 participants who met criteria for past year opioid dependence. The participants who did not return the medication diary were more likely to be younger, have more pain conditions, more mental health problems, and were more likely to meet criteria for past year pharmaceutical opioid dependence. Therefore, the proportion of participants on higher OME doses may have been underestimated, although there is no reason to expect the associations we observed here would vary. Future POINT research will include linkage to PBS dispensing data and will allow us to obtain medication profiles for those that did not return their medication diaries.
Although the POINT cohort may not be representative of all CNCP patients receiving opioids, as noted earlier, data collected from pharmacists over the recruitment window showed striking similarity in these demographic characteristics of those receiving opioids more generally and the sample recruited here. A final limitation to note is that there are a assumptions made when OME units are used as measure of opioid consumption [37] , although this is an accepted and widely used method to calculate opioid doses [50] .
Conclusion
This study demonstrated that a significant minority of people taking opioids for CNCP were taking considerable amounts of those drugs on a daily basis, and that those consuming more had a higher number of risk factors for less favorable outcomes of opioid use. Higher opioid consumption was also strongly associated with risk for dependence. Given the psychiatric comorbidity and combinations of sedative medications that were documented in this population, the risks of high-dose consumption of pharmaceutical opioids need to be weighed against clinical evidence that patients are deriving net benefit from their use.
